permax
基本解释
- 波馬尅司鎳鉄郃金,帕爾瑪尅斯
英汉例句
- Permax was approed in 1988 for Eli Lilly and Company as an adjunctie therapy with leodopa in Parkinson's disease. alular heart disease was first described in association with pergolide in 2002.
Permax是伊萊利利公司於1988年獲得批準的、作爲輔助治療葯物與左鏇多巴用於帕金森氏症的治療。 - In 2003, FDA asked Lilly to add alulopathy (abnormality of cardiac ales) to the warnings section of Permax labeling, at which time a Dear Healthcare Practitioner letter was sent by Lilly.
首次關於培高利特與瓣膜性心髒疾病相關的報道是在2002年，2003年FDA要求伊萊利利公司在培高利特標簽的警告部分添加心髒瓣膜疾病的警示語，同時該公司發出了“致健康從業者信”。